CANCER:

Rectal Cancer

Related cancers:

‹

Colorectal Cancer (901)

Colon Cancer (95)

Colorectal Adenocarcinoma (5)

Colorectal Cancer (901)

Colon Cancer (95)

Colorectal Adenocarcinoma (5)

›

KRAS mutation + ATM mutation KRAS mutation + ATM mutation	Rectal Cancer Rectal Cancer	bevacizumab Sensitive: C4 – Case Studies Onco Targets Ther - 2 weeks
No biomarker No biomarker	Rectal Cancer Rectal Cancer	FOLFIRI Sensitive: A1 - Approval
No biomarker No biomarker	Rectal Cancer Rectal Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Rectal Cancer Rectal Cancer	irinotecan Sensitive: A1 - Approval
No biomarker No biomarker	Rectal Cancer Rectal Cancer	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	FOLFOXIRI Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	FOLFOX Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	CAPOX Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	bevacizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	5-fluorouracil Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	trifluridine/tipiracil Sensitive: A2 - Guideline
HER-2 amplification HER-2 amplification	Rectal Cancer Rectal Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline
HER-2 amplification HER-2 amplification	Rectal Cancer Rectal Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline
HER-2 amplification HER-2 amplification	Rectal Cancer Rectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Rectal Cancer Rectal Cancer	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Rectal Cancer Rectal Cancer	larotrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Rectal Cancer Rectal Cancer	larotrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Rectal Cancer Rectal Cancer	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Rectal Cancer Rectal Cancer	entrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Rectal Cancer Rectal Cancer	entrectinib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Rectal Cancer Rectal Cancer	cetuximab + encorafenib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Rectal Cancer Rectal Cancer	panitumumab + encorafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	ramucirumab Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	ziv-aflibercept IV Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	5-fluorouracil + leucovorin calcium Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	mFOLFOX6 Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	regorafenib Sensitive: A2 - Guideline
UGT1A111 UGT1A111	Rectal Cancer Rectal Cancer	capecitabine + irinotecan Sensitive: B - Late Trials
No biomarker No biomarker	Rectal Cancer Rectal Cancer	FOLFIRINOX + mFOLFOX6 Sensitive: B - Late Trials
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	sintilimab Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Rectal Cancer Rectal Cancer	nivolumab Sensitive: C3 – Early Trials
TMB-H TMB-H	Rectal Cancer Rectal Cancer	nivolumab Sensitive: C3 – Early Trials
TACC3 expression TACC3 expression	Rectal Cancer Rectal Cancer	5-fluorouracil Resistant: C3 – Early Trials
TACC3 expression TACC3 expression	Rectal Cancer Rectal Cancer	FOLFOX Resistant: C3 – Early Trials
TACC3 expression TACC3 expression	Rectal Cancer Rectal Cancer	CAPOX Resistant: C3 – Early Trials
TACC3 expression TACC3 expression	Rectal Cancer Rectal Cancer	capecitabine Resistant: C3 – Early Trials
PAI1 expression PAI1 expression	Rectal Cancer Rectal Cancer	AZD1208 Sensitive: D – Preclinical

Rectal Cancer

Associations(41)

Associations
(41)